Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782985 | 0.87 | GAA (0.42) | ELANEHTTPLA2G2AGAAGFER | |
| SCHEMBL793288 | 0.82 | PDGFRA (0.54) | ELANEKMOSLC22A12HTTMYC | |
| SCHEMBL3699843 | 0.82 | ELANE (0.41) | ELANEKMOSLC22A12SMN1; SMN2 | |
| SCHEMBL17514107 | 0.82 | ELANE (0.41) | ELANEKMOSLC22A12LMNAHPGD | |
| SCHEMBL28311685 | 0.82 | SLC22A12 (0.56) | ELANEKMOSLC22A12HTT | |
| SCHEMBL11897866 | 0.80 | ESR1 (0.38) | KMOESR1SLC22A12PLA2G2A | |
| SCHEMBL11897154 | 0.80 | SLC22A12 (0.41) | ESR1SLC22A12 | |
| SCHEMBL11897091 | 0.80 | ESR1 (0.37) | ESR1HTTGAAHPGDSMN1; SMN2 | |
| SCHEMBL176815 | 0.80 | SLC22A12 (0.39) | ESR1SLC22A12HTTPLA2G2A | |
| SCHEMBL176840 | 0.79 | ESR2 (0.41) | ELANEKMOESR1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | ELANE 1921/4885KMO 625/4885ESR1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.